EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Hyloris Pharmaceuticals's Enterprise Value is €110.48 Mil.
Hyloris Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-7.62 Mil. Therefore, Hyloris Pharmaceuticals's EV-to-FCF for today is -14.50.
The historical rank and industry rank for Hyloris Pharmaceuticals's EV-to-FCF or its related term are showing as below:
FRA:52U'
s EV-to-FCF Range Over the Past 10 Years
Min: -60.65 Med: -22.62 Max: -5.9
Current: -15.02
During the past 10 years, the highest EV-to-FCF of Hyloris Pharmaceuticals was -5.90. The lowest was -60.65. And the median was -22.62.
FRA:52U's EV-to-FCF is ranked worse than 100% of 327
companies
in the Biotechnology industry
Industry Median: 16.69
vs FRA:52U: -15.02
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Hyloris Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Hyloris Pharmaceuticals's share price for today is €4.35.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Hyloris Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.230.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Hyloris Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hyloris Pharmaceuticals EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hyloris Pharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Hyloris Pharmaceuticals's EV-to-FCF falls into.
Hyloris Pharmaceuticals's current Enterprise Value is €110.48 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Hyloris Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-7.62 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hyloris Pharmaceuticals (FRA:52U) has a EV-to-FCF of -14.50 as of Jul. 08, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Hyloris Pharmaceuticals and its competitors. According to the industry distribution chart, Hyloris Pharmaceuticals ranks #999999 out of 327 companies in the Biotechnology industry.
Is Hyloris Pharmaceuticals' EV-to-FCF too high?
Hyloris Pharmaceuticals' current EV-to-FCF is -14.50. Based on the distribution chart, Hyloris Pharmaceuticals ranks #999999 out of 327 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Hyloris Pharmaceuticals has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Hyloris Pharmaceuticals' EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hyloris Pharmaceuticals ranks #999999 out of 327 companies for EV-to-FCF. This places Hyloris Pharmaceuticals in the lower half of its industry. The industry median EV-to-FCF is 16.69. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.69, based on 327 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Hyloris Pharmaceuticals and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hyloris Pharmaceuticals's current EV-to-FCF is -14.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hyloris Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hyloris Pharmaceuticals (FRA:52U) is currently considered Possible Value Trap. The stock's GF Value™ is €8.32, compared to a current price of €4.35 — trading 47.7% below its estimated fair value. The current EV-to-FCF is -14.50. Hyloris Pharmaceuticals' overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Hyloris Pharmaceuticals (FRA:52U), the current EV-to-FCF is -14.50 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hyloris Pharmaceuticals (FRA:52U) Overvalued in 2026?
Based on GuruFocus' analysis, Hyloris Pharmaceuticals stock appears to be undervalued.
The current stock price of €4.35 is trading 47.7% below its estimated GF Value™ of €8.32.
GuruFocus considers Hyloris Pharmaceuticals to be Possible Value Trap.
Key valuation signals for FRA:52U:
EV-to-FCF: -14.50
GF Value™: €8.32 vs. price of €4.35 (47.7% below fair value)
No single metric tells the full story. See the FRA:52U stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans areas such as cardiovascular, other reformulations, and established markets (high-barrier generics). It has three early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, Podofilox Ge, and Maxigesic IV. Its revenue is mainly generated in the United States.
68GF Score
Get the complete analysis for FRA:52U
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:52U has been successfully added to your 
